OverviewSuggest Edit

Codiak Biosciences is a biopharmaceutical company focused on the development of exosome-based therapeutics. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, it develops its engEx Platform to expand upon the innate properties of exosomes to design, engineer, and manufacture exosome therapeutic candidates. Codiak Biosciences utilizes its platform to generate a pipeline of engineered exosomes aimed at treating a range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular diseases, and infectious diseases.

TypePublic
Founded2015
HQCambridge, MA, US
Websitecodiakbio.com

Latest Updates

Employees (est.) (Aug 2020)101
Job Openings8
Revenue (FY, 2020)$2.9 M(+652%)
Share Price (Jul 2021)$16.6
Cybersecurity ratingAMore

Key People/Management at Codiak Biosciences

Douglas E. Williams

Douglas E. Williams

President, Chief Executive Officer, Director
Linda C. Bain

Linda C. Bain

Chief Financial Officer
Nicole Barna

Nicole Barna

Senior Vice President of Human Resources
Richard Brudnick

Richard Brudnick

Chief Business Officer and Head of Strategy
Konstantin Konstantinov

Konstantin Konstantinov

Chief Technology Officer
Yalonda Howze

Yalonda Howze

Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Corporate Secretary
Show more

Codiak Biosciences Office Locations

Codiak Biosciences has an office in Cambridge
Cambridge, MA, US (HQ)
35 Cambridgepark Dr #500
Show all (1)

Codiak Biosciences Financials and Metrics

Codiak Biosciences Revenue

Codiak Biosciences's revenue was reported to be $2.92 m in FY, 2020
USD

Revenue (FY, 2020)

2.9m

Net income (FY, 2020)

(91.7m)

EBIT (FY, 2020)

(90.9m)

Market capitalization (14-Jul-2021)

366.8m

Closing stock price (14-Jul-2021)

16.6

Cash (31-Dec-2020)

88.9m

EV

340.9m
Codiak Biosciences's current market capitalization is $366.8 m.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

388.0k2.9m

General and administrative expense

9.9m21.0m19.9m

R&D expense

28.5m59.5m74.0m

Operating expense total

46.4m80.5m93.8m
Half Year
USDH1, 2019H1, 2020

Revenue

87.0k321.0k

General and administrative expense

12.0m8.6m

R&D expense

25.2m30.0m

Operating expense total

37.2m38.6m
Quarterly
USDQ3, 2020

Revenue

954.0k

General and administrative expense

5.3m

R&D expense

30.6m

Operating expense total

36.0m
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

18.1m10.3m88.9m

Prepaid Expenses

4.8m

Current Assets

91.1m94.1m93.8m

PP&E

5.9m17.6m31.4m
Quarterly
USDQ2, 2020Q3, 2020

Cash

50.9m48.3m

Prepaid Expenses

4.0m

Current Assets

52.6m52.4m

PP&E

31.1m31.5m
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

(44.5m)(78.0m)(91.7m)

Depreciation and Amortization

1.7m2.8m4.4m

Accounts Payable

(536.0k)1.5m(378.0k)

Cash From Operating Activities

(30.6m)(1.7m)(63.4m)
Quarterly
USDQ2, 2019Q2, 2020Q3, 2020

Net Income

(35.7m)(38.4m)(73.7m)

Depreciation and Amortization

1.0m2.0m3.1m

Accounts Payable

(168.0k)

Cash From Operating Activities

27.3m(14.4m)(29.5m)
USDFY, 2018

Financial Leverage

-0.9 x
Show all financial metrics

Codiak Biosciences Operating Metrics

Q2, 2020

Products

11

Discovery Stage Products

7

Pre-Clinical Phase Products

2

Phase II Trials Products

2
Show all operating metrics

Codiak Biosciences Acquisitions / Subsidiaries

Company NameDateDeal Size
Codiak Securities Corporation

Codiak Biosciences Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Codiak Biosciences Online and Social Media Presence

Embed Graph

Codiak Biosciences News and Updates

Codiak BioSciences to Present at the Virtual William Blair Biotech Focus Conference 2021

CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that its President and Chief Executive Officer, D…

Codiak BioSciences Expands Executive Leadership

– Sriram Sathyanarayanan, Ph.D. promoted to Chief Scientific Officer –

Codiak BioSciences to Present at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference

CAMBRIDGE, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that its President and Chief Executive Officer, D…

Codiak BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Progress

– First human proof-of-concept data from exoIL-12™ program confirmed desired product profile and enabled dose selection for further evaluation in patients –

Codiak BioSciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference

CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that its President and Chief Executive Officer, Douglas E. Williams…

Codiak Biosciences Blogs

Codiak BioSciences Announces the Transition of Benny Sorensen, M.D., Ph.D. to Scientific Advisory Board Member and Clinical Consultant Roles

– Dr. Sorensen to become CEO of a start-up hemostasis and thrombosis company – CAMBRIDGE, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class

Codiak BioSciences Appoints Anne-Virginie Eggimann, M.Sc., to Board of Directors

– Executive leader with deep regulatory experience bringing innovative biopharmaceutical products from early development to market approval – CAMBRIDGE, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering

Codiak BioSciences Reports First Quarter 2021 Financial Results and Operational Progress

– Key clinical data from first in-human studies of engineered exosome therapeutic candidates, exoIL-12™ and exoSTING™, expected this year – – Data from multiple preclinical programs to be presented at ASGCT 2021 showing broad potential applications for engineered exosomes – CAMBRIDGE, Mass., May

Codiak to Present Preclinical Data Demonstrating Broad Potential Applications for Engineered Exosomes at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting

– engEx™ Platform and in vitro and in vivo findings support utility across multiple therapeutic areas – CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based

Codiak Announces Closing of $66.4 Million Public Offering, Including Full Exercise of Underwriters’ Option

Codiak Announces Closing of $66.4 Million Public Offering, Including Full Exercise of Underwriters’ Option Content Import Wed, 02/17/2021 - 16:30 Codiak Announces Closing of $66.4 Million Public Offering, Including Full Exercise of Underwriters’ Option February 17, 2021 at 4…

Codiak Announces Proposed Public Offering of Common Stock

Codiak Announces Proposed Public Offering of Common Stock Content Import Tue, 02/09/2021 - 16:18 Codiak Announces Proposed Public Offering of Common Stock February 9, 2021 at 4:17 PM EST This release is a backfill from a News Wire General …
Show more

Codiak Biosciences Frequently Asked Questions

  • When was Codiak Biosciences founded?

    Codiak Biosciences was founded in 2015.

  • Who are Codiak Biosciences key executives?

    Codiak Biosciences's key executives are Douglas E. Williams, Linda C. Bain and Nicole Barna.

  • How many employees does Codiak Biosciences have?

    Codiak Biosciences has 101 employees.

  • What is Codiak Biosciences revenue?

    Latest Codiak Biosciences annual revenue is $2.9 m.

  • What is Codiak Biosciences revenue per employee?

    Latest Codiak Biosciences revenue per employee is $28.9 k.

  • Who are Codiak Biosciences competitors?

    Competitors of Codiak Biosciences include Nimbus Therapeutics, Takeda Pharmaceutical and Aduro Biotech.

  • Where is Codiak Biosciences headquarters?

    Codiak Biosciences headquarters is located at 35 Cambridgepark Dr #500, Cambridge.

  • Where are Codiak Biosciences offices?

    Codiak Biosciences has an office in Cambridge.

  • How many offices does Codiak Biosciences have?

    Codiak Biosciences has 1 office.